Please check your internet connection and try again.
# L-Ornithine L-Aspartate (Hepamerz)
## Overview
L-ornithine L-aspartate (LOLA) is a combination of two amino acids used in the management of hepatic encephalopathy. It is believed to work by promoting the detoxification of ammonia in the liver and brain.
## Primary Indications
* Hepatic encephalopathy (overt and subclinical)
## Adult Dosing
* **Oral:** Typically 6-18 grams per day, divided into 3 doses. A common starting dose is 9 grams per day.
* **Intravenous:** Typically 5-10 grams per day, infused over 30-60 minutes. The exact dose and duration depend on the severity of hepatic encephalopathy and local protocols.
## Pediatric Dosing
* There is limited pediatric data. Dosing should be individualized and guided by specialist recommendations.
## Dose Adjustments
* **Renal Impairment:** Caution is advised, but no specific dose adjustments are universally established. Ammonia levels and clinical response should guide therapy.
* **Hepatic Impairment:** This drug is indicated for hepatic impairment; no dose adjustment is typically needed beyond what is required to manage the encephalopathy.
## Contraindications
* Hypersensitivity to L-ornithine L-aspartate or its components.
* Severe renal impairment (oliguria, anuria).
## Adverse Effects
* Gastrointestinal: Nausea, vomiting, abdominal discomfort, diarrhea.
* Neurological: Drowsiness, dizziness (rare).
* Electrolyte disturbances (rare, particularly with IV administration).
## Key Drug Interactions
* No significant drug interactions are well-established. However, caution with other medications affecting ammonia metabolism or renal function may be warranted.
## Monitoring
* Clinical signs and symptoms of hepatic encephalopathy (e.g., confusion, asterixis).
* Ammonia levels (though correlation with clinical status can be variable).
* Renal function and electrolytes, especially with IV administration or in patients with underlying renal issues.
## Clinical Pearls
* LOLA is most effective when initiated early in the course of hepatic encephalopathy.
* Oral administration may be limited by gastrointestinal side effects.
* IV administration is typically reserved for more severe cases or when oral intake is not feasible.
* Treatment should be continued as long as the risk of hepatic encephalopathy persists.
***
*This information is intended for clinical pharmacists and should not replace independent clinical judgment. Always consult the most current prescribing information and relevant literature before making therapeutic decisions.*
